These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21263144)

  • 1. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.
    Groh WJ
    Neurology; 2011 Jan; 76(4):409; author reply 409. PubMed ID: 21263144
    [No Abstract]   [Full Text] [Related]  

  • 2. Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy.
    Wahbi K; Bassez G; Duchateau J; Salort-Campana E; Vicart S; Desaphy JF; Labombarda F; Sellal JM; Deharo JC
    Arch Cardiovasc Dis; 2024; 117(6-7):450-456. PubMed ID: 38677940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.
    Logigian EL; Martens WB; Moxley RT; McDermott MP; Dilek N; Wiegner AW; Pearson AT; Barbieri CA; Annis CL; Thornton CA; Moxley RT
    Neurology; 2010 May; 74(18):1441-8. PubMed ID: 20439846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arrhythmia exacerbation after sodium channel blockade in myotonic dystrophy type 1.
    Otten RF; Scherschel JA; Lopshire JC; Bhakta D; Pascuzzi RM; Groh WJ
    Muscle Nerve; 2009 Nov; 40(5):901-2. PubMed ID: 19623641
    [No Abstract]   [Full Text] [Related]  

  • 5. Myotonic dystrophy type 1.
    Nguyen CE; Campbell C
    CMAJ; 2016 Oct; 188(14):1033. PubMed ID: 27270116
    [No Abstract]   [Full Text] [Related]  

  • 6. Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Heatwole C; Luebbe E; Rosero S; Eichinger K; Martens W; Hilbert J; Dekdebrun J; Dilek N; Zizzi C; Johnson N; Puwanant A; Tawil R; Schifitto G; Beck CA; Richeson JF; Zareba W; Thornton C; McDermott MP; Moxley R
    Neurology; 2021 Jan; 96(2):e228-e240. PubMed ID: 33046619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine-induced sinus tachycardia in a patient with Myotonic Dystrophy type 1.
    Russo V; Nigro G; Papa AA; Rago A; Della Cioppa N; Cristiano A; Russo MG
    Acta Myol; 2014 Oct; 33(2):104-6. PubMed ID: 25709381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voltage-Gated Sodium Channel Blockers: Synthesis of Mexiletine Analogues and Homologues.
    Catalano A; Franchini C; Carocci A
    Curr Med Chem; 2021; 28(8):1535-1548. PubMed ID: 32364065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of fulminant Type 1 diabetes associated with mexiletine hypersensitivity syndrome.
    Seino Y; Yamauchi M; Hirai C; Okumura A; Kondo K; Yamamoto M; Okazaki Y
    Diabet Med; 2004 Oct; 21(10):1156-7. PubMed ID: 15384968
    [No Abstract]   [Full Text] [Related]  

  • 10. [Successful treatment of incontinence of feces in myotonic muscular dystrophy by mexiletine].
    Hayashi T; Ichiyama T; Tanaka H; Koga M; Okino A
    No To Hattatsu; 1991 May; 23(3):310-2. PubMed ID: 2043377
    [No Abstract]   [Full Text] [Related]  

  • 11. Mexiletine-induced severe skin eruption, fever, eosinophilia, atypical lymphocytosis, and liver dysfunction.
    Higa K; Hirata K; Dan K
    Pain; 1997 Oct; 73(1):97-9. PubMed ID: 9414061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of mexiletine for treatment of myotonia in myotonic dystrophy type 1.
    Salguero-Bodes R; Ruiz-Curiel A; Palomino-Doza J; Valverde-Gómez M; Domínguez-González C; Arribas-Ynsaurriaga F
    Rev Esp Cardiol (Engl Ed); 2021 Nov; 74(11):986-987. PubMed ID: 34120884
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute exanthematous pustular drug eruption induced by mexiletine.
    Sasaki K; Yamamoto T; Kishi M; Yokozeki H; Nishioka K
    Eur J Dermatol; 2001; 11(5):469-71. PubMed ID: 11525960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mexitil, a new anti-arrhythmia agent].
    Heinrich K
    Med Klin; 1980 Mar; 75(6):235-7. PubMed ID: 7393119
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug-induced hypersensitivity syndrome complicated with concurrent fulminant type 1 diabetes mellitus and Hashimoto's thyroiditis.
    Minegaki Y; Higashida Y; Ogawa M; Miyachi Y; Fujii H; Kabashima K
    Int J Dermatol; 2013 Mar; 52(3):355-7. PubMed ID: 23414162
    [No Abstract]   [Full Text] [Related]  

  • 16. [Méxiletine. Action on heart rhythm disorders].
    Lellouche D; Bougherbal R
    Nouv Presse Med; 1975 Feb; 4(5):351-2. PubMed ID: 1093125
    [No Abstract]   [Full Text] [Related]  

  • 17. Expert Insights from a Delphi-driven Neurologists' Panel: Real-world Mexiletine use in Patients with Myotonic Disorders in Italy.
    Lidonnici D; Brambilla P; Ravasio R; Zozulya-Weidenfeller A; Beiderbeck A; van Aswegen M; Oliveira R; Sansone VA
    J Neuromuscul Dis; 2024; 11(2):411-423. PubMed ID: 38306059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation.
    Eroğlu S; Ozin B; Ozbiçer S; Müderrisoğlu H
    Turk Kardiyol Dern Ars; 2009 Jul; 37(5):337-40. PubMed ID: 19875908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mexiletine in the treatment of blepharospasm: experience with the first three patients.
    Ohara S; Tsuyuzaki J; Hayashi R
    Mov Disord; 1999 Jan; 14(1):173-5. PubMed ID: 9918369
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevalence of type 1 Brugada ECG pattern after administration of Class 1C drugs in patients with type 1 myotonic dystrophy: Myotonic dystrophy as a part of the Brugada syndrome.
    Maury P; Audoubert M; Cintas P; Rollin A; Duparc A; Mondoly P; Chiriac AM; Acket B; Zhao X; Pasquié JL; Cardin C; Delay M; Sadron M; Carrié D; Galinier M; Davy JM; Arne-Bès MC; Raczka F
    Heart Rhythm; 2014 Oct; 11(10):1721-7. PubMed ID: 25016148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.